Compositions for sensitive skin

ABSTRACT

Disclosed are compositions and methods for their use that include a combination of escin, Ruscus aculeatus root extract, ammonium glycyrrhizate, Centella asiatica extract, hydrolyzed yeast protein, and Calendula officinalis flower extract.

CROSS REFERENCE TO RELATED APPLICATIONS

This application is a continuation of U.S. application Ser. No.16/234,028, filed Dec. 27, 2018, which is a continuation of U.S.application Ser. No. 15/796,958, filed Oct. 30, 2017 (U.S. Pat. No.10,245,282), which is a continuation of U.S. application Ser. No.14/550,664, filed Nov. 21, 2014 (U.S. Pat. No. 9,801,900), which claimsthe benefit of U.S. Provisional Application No. 61/921,803, filed Dec.30, 2013, U.S. Provisional Application No. 61/913,551, filed Decemebr 9,2013, and U.S. Provisonal Application No. 61/907,836, filed Nov. 22,2013. The contents of the referenced applications are incorporated intothe present application by reference.

BACKGROUND OF THE INVENTION A. Field of the Invention

The present invention relates to a combination of ingredients that canbe used to treat or prevent erythema (i.e., reddened/flushed skin) inpeople having sensitive skin. This combination of ingredients can beincluded in a wide-range of product formulations (e.g., toners, gels,masks, etc.).

B. Description of Related Art

Sensitive skin is a condition where the skin has a tendency towardsflushing, reddening, or blushing (i.e., erythema) when exposed tostimuli such as UV light, heat, cold, chemicals, or active ingredientsin skin formulations, etc. One of the issues in the cosmetics industryis that active ingredients known to potentially cause erythema insensitive skin are needed to treat a given skin condition such as finelines and wrinkles, sagging skin, acne, etc. Therefore, people withsensitive skin either have to avoid such products or end up purchasingadditional products that can help alleviate the aforementioned symptomsassociated with sensitive skin.

SUMMARY OF THE INVENTION

The present invention offers a solution to the aforementioned problems.The solution is premised on a discovery of a combination ofingredients—hydrolyzed algin, escin, Ruscus aculeatus root extract,ammonium glycyrrhizate, Centella asiatica extract, hydrolyzed yeastprotein, and Calendula officinalis flower extract—that can be used toalleviate or even prevent symptoms associated with sensitive skin (e.g.,erythema or skin inflammation). This combination of ingredients can beused in a variety of product formulations (e.g., toners, cleansers,emulsions such as lotions or creams, masks, gels, etc.) along with otherskin-active ingredients that are known to cause erythema when applied tosensitive skin. That is to say, this combination of ingredients can beused with other known skin-active ingredients so as to treat a givenskin condition (e.g., with the known skin active) and prevent or reducethe symptoms associated with sensitive skin (e.g., with theaforementioned combination of ingredients). Without wishing to be boundby theory, it is believed that the discovered combination of ingredientsprovides for a strong anti-oxidative effect (see Examples) and/or whichinterferes with various steps in the inflammatory process/cascade,thereby reducing the flushing/blushing/reddening that is typically seenwith sensitive skin.

In one instance, there is disclosed a topical skin compositioncomprising a combination of hydrolyzed algin, escin, Ruscus aculeatusroot extract, ammonium glycyrrhizate, Centella asiatica extract,hydrolyzed yeast protein, and Calendula officinalis flower extract.Alternatively, an one or any combination said ingredients can be used inthe compositions of the present invention. For instance, a combinationof escin, Ruscus aculeatus root extract, ammonium glycyrrhizate,Centella asiatica extract, hydrolyzed yeast protein, and Calendulaofficinalis flower extract can be used as an anti-oxidant on skin inneed of an anti-oxidant. The amounts of the ingredients within thecomposition can vary (e.g., amounts can be as low as 0.000001% to ashigh as 60% w/w or any ranger therein). In one instance, the compositionincludes 0.0001% to 1% w/w of escin, 0.0001% to 1% w/w of Ruscusaculeatus root extract, 0.0001% to 1% w/w of ammonium glycyrrhizate,0.0001% to 1% w/w of Centella asiatica extract, 0.0001% to 1% w/w ofhydrolyzed yeast protein, and 0.0001% to 1% w/w of Calendula officinalisflower extract and can also include 0.0001% to 1% w/w of hydrolyzedalgin. In some aspects, disclosed are methods of applying any of thetopical skin compositions disclosed herein comprising applying saidcomposition to skin. In some aspects, the composition is applied tosensitive skin.

In another aspect, there is disclosed a topical skin compositionformulated as a toner comprising any one of, any combination of, or allof escin, Ruscus aculeatus root extract, ammonium glycyrrhizate,Centella asiatica extract, hydrolyzed yeast protein, Calendulaofficinalis flower extract, water, butylene glycol, glycerin, propyleneglycol, diazolidinyl urea, PPG-5-ceteth-20, methylparaben, sodiumcitrate, disodium EDTA, buteth-3, propylparaben, citric acid, sodiumbenzotriazolyl butylphenol sulfonate, panthenol, hydrolyzed algin,sodium hyaluronate, simethicone, tributyl citrate, phenoxyethanol,cyclotetrasiloxane, potassium sorbate, sodium benzoate,cyclopentasiloxane, cyclohexasiloxane, and Opuntia tuna fruit extract.The amounts of the ingredients within the composition can vary (e.g.,amounts can be as low as 0.000001% to as high as 60% w/w or any rangertherein). In one instance, the composition includes 0.0001% to 1% w/w ofescin, 0.0001% to 1% w/w of Ruscus aculeatus root extract, 0.0001% to 1%w/w of ammonium glycyrrhizate, 0.0001% to 1% w/w of Centella asiaticaextract, 0.0001% to 1% w/w of hydrolyzed yeast protein, 0.0001% to 1%w/w of Calendula officinalis flower extract, 70% to 90% w/w of water, 5%to 7% w/w of butylene glycol, 3% to 6% w/w of glycerin, 0.1% to 1.0% w/wof propylene glycol, 0.1% to 0.5% w/w of diazolidinyl urea, 0.01% to0.3% w/w of PPG-5-ceteth-20, 0.05% to 0.5% w/w of methylparaben, 0.05%to 0.5% w/w of sodium citrate, 0.05% to 0.5% w/w of disodium EDTA,0.005% to 0.05% w/w of buteth-3, 0.005% to 0.05% w/w of propylparaben,0.005% to 0.05% w/w of citric acid, 0.005% to 0.05% w/w of sodiumbenzotriazolyl butylphenol sulfonate, 0.005% to 0.05% w/w of panthenol,0.001% to 0.01% w/w of hydrolyzed algin, 0.001% to 0.01% w/w of sodiumhyaluronate, 0.0001% to 0.001% w/w of simethicone, 0.0001% to 0.001% w/wof tributyl citrate, 0.0001% to 0.001% w/w of phenoxyethanol, 0.0001% to0.001% w/w of cyclotetrasiloxane, 0.0001% to 0.001% w/w of potassiumsorbate, 0.0001% to 0.001% w/w of sodium benzoate, 0.0001% to 0.001% w/wof cyclopentasiloxane, 0.0001% to 0.001% w/w of cyclohexasiloxane, and0.0001% to 0.1% w/w of Opuntia tuna fruit extract. In some aspects, alsodisclosed are methods of applying the disclosed compositions to skinwithin 5 minutes after the skin has been cleansed by a cleansingcomposition. In some aspects, a moisturizer is applied to skin within 5minutes after applying any one of these topical skin compositions toskin.

In another aspect, there is disclosed a topical skin compositionformulated as a mask comprising any one of, any combination of, or allof escin, Ruscus aculeatus root extract, ammonium glycyrrhizate,Centella asiatica extract, hydrolyzed yeast protein, Calendulaofficinalis flower extract, water, pentylene glycol, polysilicone-11,hydroxyethyl acrylate/sodium acryloyldimethyl taurate copolymer,dimethicone, squalane, glyceryl undecylenate, benzyl alcohol, silica,butylene glycol, triethanolamine, polysorbate 60, acrylates/C10-30 alkylacrylate crosspolymer, hydroxypropyl cyclodextrin, sorbitan isostearate,panthenol, hydrolyzed algin, glycerin, iodopropynyl butylcarbamate,phenoxyethanol, sodium citrate, sodium benzoate, citric acid, potassiumsorbate, and Opuntia tuna fruit extract. The amounts of the ingredientswithin the composition can vary (e.g., amounts can be as low as0.000001% to as high as 60% w/w or any ranger therein). In one instance,the composition includes 0.0001% to 1% w/w of escin, 0.0001% to 1% w/wof Ruscus aculeatus root extract, 0.0001% to 1% w/w of ammoniumglycyrrhizate, 0.0001% to 1% w/w of Centella asiatica extract, 0.0001%to 1% w/w of hydrolyzed yeast protein, 0.0001% to 1% w/w of Calendulaofficinalis flower extract, 75% to 95% w/w of water, 4% to 6% w/w ofpentylene glycol, 1% to 4% w/w of polysilicone-11, 1% to 3% w/w ofhydroxyethyl acrylate/sodium acryloyldimethyl taurate copolymer, 1% to3% w/w of dimethicone, 1% to 3% w/w of squalane, 0.5% to 1.5% w/w ofglyceryl undecylenate, 0.5% to 1.5% w/w of benzyl alcohol, 0.1% to 1.0%w/w of silica, 0.1% to 1.0% w/w of butylene glycol, 0.1% to 1.0% w/w oftriethanolamine, 0.1% to 1.0% w/w of polysorbate 60, 0.1% to 1.0% w/w ofacrylates/C10-30 alkyl acrylate crosspolymer, 0.01% to 0.1% w/w ofhydroxypropyl cyclodextrin, 0.01% to 0.1% w/w of sorbitan isostearate,0.01% to 0.1% w/w of panthenol, 0.01% to 0.1% w/w of hydrolyzed algin,0.01% to 0.1% w/w of glycerin, 0.001% to 0.1% w/w of iodopropynylbutylcarbamate, 0.001% to 0.1% w/w of phenoxyethanol, 0.0001% to 0.001%w/w of sodium citrate, 0.0001% to 0.001% w/w of sodium benzoate, 0.0001%to 0.001% w/w of citric acid, and 0.0001% to 0.001% w/w of potassiumsorbate. In some aspects, also disclosed are methods of applying any oneof the topical skin compositions of disclosed herein to skin comprisingapplying said composition to skin, wherein the composition remains onthe skin for 1 to 12 hours.

In another aspect, there is disclosed a topical skin compositionformulated as a cream or gel capable of reducing the appearance of darkcircles or puffy eyes comprising any one of, any combination of, or allof hydrolyzed align, escin, Ruscus aculeatus root extract, ammoniumglycyrrhizate, Centella asiatica extract, hydrolyzed yeast protein,Calendula officinalis flower extract, water, glycerin, pentylene glycol,glycereth-26, propylene glycol, triethanolamine, acrylates/C10-30 alkylacrylate crosspolymer, diazolidinyl urea, hydroxyethylcellulose, sodiumpolyacrylate, methylparaben, disodium EDTA, butylene glycol,phenoxyethanol, caprylyl glycol, propylparaben, panthenol, and Opuntiatuna fruit extract. The amounts of the ingredients within thecomposition can vary (e.g., amounts can be as low as 0.000001% to ashigh as 60% w/w or any ranger therein). In one instance, the compositionincludes 0.005% to 0.05% w/w of hydrolyzed align, 0.0001% to 1% w/w ofescin, 0.0001% to 1% w/w of Ruscus aculeatus root extract, 0.0001% to 1%w/w of ammonium glycyrrhizate, 0.0001% to 1% w/w of Centella asiaticaextract, 0.0001% to 1% w/w of hydrolyzed yeast protein, 0.0001% to 1%w/w of Calendula officinalis flower extract, 75% to 95% w/w of water, 3to 7% by weight of glycerin, 3 to 7% by weight of pentylene glycol, 1 to3% by weight of glycereth-26, 0.3 to 0.7% by weight of propylene glycol,0.3 to 0.7% by weight of triethanolamine, 0.1 to 0.5% by weight ofacrylates/C10-30 alkyl acrylate crosspolymer, 0.1 to 0.5% by weight ofdiazolidinyl urea, 0.1 to 0.5% by weight of hydroxyethylcellulose, 0.1to 0.5% by weight of sodium polyacrylate, 0.1 to 0.5% by weight ofmethylparaben, 0.05 to 0.5% by weight of disodium EDTA, 0.05 to 0.1% byweight of butylene glycol, 0.03 to 0.07% by weight of phenoxyethanol,0.03 to 0.07% by weight of caprylyl glycol, 0.01 to 0.05% by weight ofpropylparaben, and, 0.01 to 0.05% by weight of panthenol.

In yet another aspect, there is disclosed a topical skin compositionformulated as a cream or gel capable of reducing the appearance of darkcircles or puffy eyes comprising any one of, any combination of, or allof escin, Ruscus aculeatus root extract, ammonium glycyrrhizate,Centella asiatica extract, hydrolyzed yeast protein, Calendulaofficinalis flower extract, water, glycerin, pentylene glycol,glycereth-26, benzyl alcohol, triethanolamine, acrylates/C10-30 alkylacrylate crosspolymer, hydroxyethylcellulose, sodium polyacrylate,disodium EDTA, hydroxypropyl cyclodextrin, butylene glycol,phenoxyethanol, caprylyl glycol, panthenol, iodopropynyl butylcarbamate,hydrolyzed algin, mica, titanium dioxide, sodium citrate, potassiumsorbate, sodium benzoate, citric acid, and Opuntia tuna fruit extract.The amounts of the ingredients within the composition can vary (e.g.,amounts can be as low as 0.000001% to as high as 60% w/w or any rangertherein). In one instance, the composition includes 0.0001% to 1% w/w ofescin, 0.0001% to 1% w/w of Ruscus aculeatus root extract, 0.0001% to 1%w/w of ammonium glycyrrhizate, 0.0001% to 1% w/w of Centella asiaticaextract, 0.0001% to 1% w/w of hydrolyzed yeast protein, 0.0001% to 1%w/w of Calendula officinalis flower extract, 75% to 95% w/w of water, 3%to 7% w/w of glycerin, 2% to 5% w/w of pentylene glycol, 1% to 3% w/w ofglycereth-26, 0.3% to 1.5% w/w of benzyl alcohol, 0.1% to 1.5% w/w oftriethanolamine, 0.1% to 0.7% w/w of acrylates/C10-30 alkyl acrylatecrosspolymer, 0.01% to 1.0% w/w of hydroxyethylcellulose, 0.01% to 1.0%w/w of sodium polyacrylate, 0.01% to 1.0% w/w of disodium EDTA, 0.01% to1.0% w/w of hydroxypropyl cyclodextrin, 0.01% to 1.0% w/w of butyleneglycol, 0.01% to 1.0% w/w of phenoxyethanol, 0.01% to 0.1% w/w ofcaprylyl glycol, 0.005% to 0.1% w/w of panthenol, 0.001% to 0.03% w/w ofiodopropynyl butylcarbamate, 0.001% to 0.003% w/w of hydrolyzed algin,0.001% to 0.03% w/w of mica, 0.001% to 0.03% w/w of titanium dioxide,0.0001% to 0.0003% w/w of sodium citrate, 0.0001% to 0.0003% w/w ofpotassium sorbate, 0.0001% to 0.0003% w/w of sodium benzoate, and0.0001% to 0.0003% w/w of citric acid.

Also contemplated are methods of treating erythemic skin or erythemacomprising topically applying any of the aforementioned compositions toskin that has or is likely to develop erythema. Skin likely to developerythema includes people that have sensitive skin. Erythema typicallyresults from an increase in blood flow to the surface of the skin. Thecompositions can also be used to treat skin inflammation by reducingTNF-α, IL-6, IL-8, IL-10, IL-12 p40, GM-CSF cytokine production, and/orCGRP production in the skin. The compositions can also be used as anantioxidant to treat a wide range of skin conditions such as fine lines,wrinkles, sagging skin. For instance, the anti-oxidative effects of thecombination of ingredients can be used to prevent or reduce theformation of reactive oxygen species (ROS) or can prevent ROS frominteracting with cellular mechanisms within the skin.

The compositions of the present invention can also include any one of,any combination of, or all of the following additional ingredients:water, a chelating agent, a moisturizing agent, a preservative, athickening agent, a silicone containing compound, an essential oil, astructuring agent, a vitamin, a pharmaceutical ingredient, or anantioxidant, or any combination of such ingredients or mixtures of suchingredients. In certain aspects, the composition can include at leasttwo, three, four, five, six, seven, eight, nine, ten, or all of theseadditional ingredients identified in the previous sentence. Non-limitingexamples of these additional ingredients are identified throughout thisspecification and are incorporated into this section by reference. Theamounts of such ingredients can range from 0.0001% to 99.9% by weight orvolume of the composition, or any integer or range in between asdisclosed in other sections of this specification, which areincorporated into this paragraph by reference.

Also disclosed in the context of the present invention are Embodiments 1to 22. Embodiment 1 is a topical skin composition comprising aneffective amount of hydrolyzed algin, escin, Ruscus aculeatus rootextract, ammonium glycyrrhizate, Centella asiatica extract, hydrolyzedyeast protein, and Calendula officinalis flower extract, wherein thecomposition is capable of reducing cytokine production and reducingoxidative damage in skin cells. Embodiment 2 is the topical skincomposition of Embodiment 1, further comprising between 80 to 90% byweight of water. Embodiment 3 is the topical skin composition ofEmbodiment 2, comprising 0.005 to 0.05% by weight of hydrolyzed algin.Embodiment 4 is the topical skin composition of Embodiment 3, comprising0.001 to 0.05% by weight of escin, 0.001 to 0.01% by weight of Ruscusaculeatus root extract, 0.001 to 0.01% by weight of ammoniumglycyrrhizate, 0.0005 to 0.005% by weight of Centella asiatica extract,0.0003 to 0.003% by weight of hydrolyzed yeast protein, and 0.0003 to0.003% by weight of Calendula officinalis flower extract. Embodiment 5is the topical skin composition of Embodiment 3, further comprisingOpuntia tuna fruit extract. Embodiment 6 is the topical skin compositionof any one of Embodiments 1 to 5, wherein the composition furtherincludes: butylene glycol; glycerin; propylene glycol; diazolidinylurea; PPG-5-ceteth-20; methylparaben; sodium citrate; disodium EDTA;buteth-3; propylparaben; citric acid; sodium benzotriazolyl butylphenolsulfonate; and panthenol. Embodiment 7 is the topical skin compositionof Embodiment 6, wherein the composition includes: 5 to 7% by weight ofbutylene glycol; 3 to 5% by weight of glycerin; 0.3 to 0.7% by weight ofpropylene glycol; 0.1 to 0.5% by weight of diazolidinyl urea; 0.1 to0.5% by weight of PPG-5-ceteth-20; 0.1 to 0.5% by weight ofmethylparaben; 0.05 to 0.1% by weight of sodium citrate; 0.03 to 0.07%by weight of disodium EDTA; 0.03 to 0.07% by weight of buteth-3; 0.01 to0.05% by weight of propylparaben; 0.01 to 0.05% by weight of citricacid; 0.01 to 0.05% by weight of sodium benzotriazolyl butylphenolsulfonate; and 0.01 to 0.05% by weight of panthenol. Embodiment 8 is thetopical skin composition of any one of Embodiments 1 to 5, wherein thecomposition further includes: glycerin; pentylene glycol; glycereth-26;propylene glycol; triethanolamine; acrylates/C10-30 alkyl acrylatecrosspolymer; diazolidinyl urea; hydroxyethylcellulose; sodiumpolyacrylate; methylparaben; disodium EDTA; butylene glycol;phenoxyethanol; caprylyl glycol; propylparaben; and panthenol.Embodiment 9 is the topical skin composition of Embodiment 8, whereinthe composition includes: 3 to 7% by weight of glycerin; 3 to 7% byweight of pentylene glycol; 1 to 3% by weight of glycereth-26; 0.3 to0.7% by weight of propylene glycol; 0.3 to 0.7% by weight oftriethanolamine; 0.1 to 0.5% by weight of acrylates/C10-30 alkylacrylate crosspolymer; 0.1 to 0.5% by weight of diazolidinyl urea; 0.1to 0.5% by weight of hydroxyethylcellulose; 0.1 to 0.5% by weight ofsodium polyacrylate; 0.1 to 0.5% by weight of methylparaben; 0.05 to0.5% by weight of disodium EDTA; 0.05 to 0.1% by weight of butyleneglycol; 0.03 to 0.07% by weight of phenoxyethanol; 0.03 to 0.07% byweight of caprylyl glycol; 0.01 to 0.05% by weight of propylparaben; and0.01 to 0.05% by weight of panthenol. Embodiment 10 is the topical skincomposition of any one of Embodiments 1 to 5, wherein the compositionfurther includes: pentylene glycol; polysilicone-11; hydroxyethylacrylate/sodium acryloyldimethyl taurate copolymer; dimethicone;squalane; glyceryl undecylenate; silica; butylene glycol;triethanolamine; polysorbate 60; acrylates/C10-30 alkyl acrylatecrosspolymer; hydroxypropyl cyclodextrin; sorbitan isostearate;panthenol; and glycerin. Embodiment 11 is the topical skin compositionof Embodiment 10, wherein the composition includes: 3 to 7% by weight ofpentylene glycol; 1 to 5% by weight of polysilicone-11; 1 to 5% byweight of hydroxyethyl acrylate/sodium acryloyldimethyl tauratecopolymer; 1 to 3% by weight of dimethicone; 1 to 3% by weight ofsqualane; 0.5 to 2% by weight of glyceryl undecylenate; 0.3 to 0.7% byweight of silica; 0.1 to 0.5% by weight of butylene glycol; 0.1 to 0.5%by weight of triethanolamine; 0.1 to 0.5% by weight of polysorbate 60;0.1 to 0.5% by weight of acrylates/C10-30 alkyl acrylate crosspolymer;0.05 to 0.1% by weight of hydroxypropyl cyclodextrin; 0.05 to 0.1% byweight of sorbitan isostearate; 0.03 to 0.07% by weight of panthenol;and 0.03 to 0.07% by weight of glycerin. Embodiment 12 is the topicalskin composition of Embodiment 11, wherein the composition furtherincludes benzyl alcohol. Embodiment 13 is the topical skin compositionof Embodiment 12, wherein the composition includes 0.1 to 1% by weightof benzyl alcohol. Embodiment 14 is the topical skin composition of anyone of Embodiments 1 to 5, wherein the composition further includes:glycerin; pentylene glycol; glycereth-26; benzyl alcohol;triethanolamine; acrylates/C10-30 alkyl acrylate crosspolymer;hydroxyethylcellulose; sodium polyacrylate; disodium EDTA; hydroxypropylcyclodextrin; butylene glycol; phenoxyethanol; caprylyl glycol; andpanthenol. Embodiment 15 is the topical skin composition of Embodiment14, wherein the composition includes: 3 to 7% by weight of glycerin; 2to 5% by weight of pentylene glycol; 1 to 3% by weight of glycereth-26;0.3 to 1.5% by weight of benzyl alcohol; 0.1 to 1.5% by weight oftriethanolamine; 0.1 to 0.7% by weight of acrylates/C10-30 alkylacrylate crosspolymer; 0.01 to 1.0% by weight of hydroxyethylcellulose;0.01 to 1.0% by weight of sodium polyacrylate; 0.01 to 1.0% by weight ofdisodium EDTA; 0.01 to 1.0% by weight of hydroxypropyl cyclodextrin;0.01 to 1.0% by weight of butylene glycol; 0.01 to 1.0% by weight ofphenoxyethanol; 0.01 to 0.1% by weight of caprylyl glycol; and 0.005 to0.1% by weight of panthenol. Embodiment 16 is a method of reducingpro-inflammatory cytokine production in skin cells and protecting skinfrom oxidative damage from free radicals comprising topically applyingthe composition of any one of Embodiments 1 to 15 to skin in needthereof, wherein said composition reduces pro-inflammatory cytokineproduction in skin cells and protects skin from oxidative damage fromfree radicals. Embodiment 17 is the method of Embodiment 16, wherein thepro-inflammatory cytokine is TNF-α, IL-6, IL-8, IL-10, IL-12 p40, orGM-CSF, or any combination or all thereof. Embodiment 18 is the methodof Embodiment 17, wherein the composition is applied to erythemic,sensitive, or inflamed skin. Embodiment 19 is the method of Embodiment17, wherein the composition is applied to dry, flaky, or itchy skin.Embodiment 20 is a method of reducing CGRP production in skin cells andprotecting skin from oxidative damage from free radicals comprisingtopically applying the composition of any one of Embodiments 1 to 15 toskin in need thereof, wherein said composition reduces CGRP productionin skin cells and protects skin from oxidative damage from freeradicals. Embodiment 21 is the method of Embodiment 20, wherein thecomposition is applied to erythemic, sensitive, or inflamed skin.Embodiment 22 is the method of Embodiment 20, wherein the composition isapplied to dry, flaky, or itchy skin.

Kits that include the compositions of the present invention are alsocontemplated. In certain embodiments, the composition is comprised in acontainer. The container can be a bottle, dispenser, or package. Thecontainer can dispense a pre-determined amount of the composition. Incertain aspects, the compositions is dispensed in a spray, dollop, orliquid. The container can include indicia on its surface. The indiciacan be a word, an abbreviation, a picture, or a symbol.

It is also contemplated that the compositions disclosed throughout thisspecification can be used as a leave-on or rinse-off composition. By wayof example, a leave-on composition can be one that is topically appliedto skin and remains on the skin for a period of time (e.g., at least 5,6, 7, 8, 9, 10, 20, or 30 minutes, or at least 1, 2, 3, 4, 5, 6, 7, 8,9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23 or 24 hours,or overnight or throughout the day). Alternatively, a rinse-offcomposition can be a product that is intended to be applied to the skinand then removed or rinsed from the skin (e.g., with water) within aperiod of time such as less than 5, 4, 3, 2, or 1 minute. An example ofa rinse of composition can be a skin cleanser, shampoo, conditioner, orsoap. An example of a leave-on composition can be a skin moisturizer,sunscreen, mask, overnight cream, or a day cream.

It is contemplated that any embodiment discussed in this specificationcan be implemented with respect to any method or composition of theinvention, and vice versa. Furthermore, compositions of the inventioncan be used to achieve methods of the invention.

In one embodiment, compositions of the present invention can bepharmaceutically or cosmetically elegant or can have pleasant tactileproperties. “Pharmaceutically elegant,” “cosmetically elegant,” and/or“pleasant tactile properties” describes a composition that hasparticular tactile properties which feel pleasant on the skin (e.g.,compositions that are not too watery or greasy, compositions that have asilky texture, compositions that are non-tacky or sticky, etc.).Pharmaceutically or cosmetically elegant can also relate to thecreaminess or lubricity properties of the composition or to the moistureretaining properties of the composition.

“Topical application” means to apply or spread a composition onto thesurface of lips or keratinous tissue. “Topical skin composition”includes compositions suitable for topical application on lips orkeratinous tissue. Such compositions are typicallydermatologically-acceptable in that they do not have undue toxicity,incompatibility, instability, allergic response, and the like, whenapplied to lips or skin. Topical skin care compositions of the presentinvention can have a selected viscosity to avoid significant dripping orpooling after application to skin.

“Keratinous tissue” includes keratin-containing layers disposed as theoutermost protective covering of mammals and includes, but is notlimited to, lips, skin, hair and nails.

The term “about” or “approximately” are defined as being close to asunderstood by one of ordinary skill in the art, and in one non-limitingembodiment the terms are defined to be within 10%, preferably within 5%,more preferably within 1%, and most preferably within 0.5%.

The term “substantially” and its variations are defined as being largelybut not necessarily wholly what is specified as understood by one ofordinary skill in the art, and in one non-limiting embodimentsubstantially refers to ranges within 10%, within 5%, within 1%, orwithin 0.5%.

The terms “inhibiting” or “reducing” or any variation of these termsincludes any measurable decrease or complete inhibition to achieve adesired result. The terms “promote” or “increase” or any variation ofthese terms includes any measurable increase or production of a proteinor molecule (e.g., matrix proteins such as fibronectin, laminin,collagen, or elastin or molecules such as hyaluronic acid) to achieve adesired result.

The term “effective,” as that term is used in the specification and/orclaims, means adequate to accomplish a desired, expected, or intendedresult.

The use of the word “a” or “an” when used in conjunction with the term“comprising” in the claims and/or the specification may mean “one,” butit is also consistent with the meaning of “one or more,” “at least one,”and “one or more than one.”

As used in this specification and claim(s), the words “comprising” (andany form of comprising, such as “comprise” and “comprises”), “having”(and any form of having, such as “have” and “has”), “including” (and anyform of including, such as “includes” and “include”) or “containing”(and any form of containing, such as “contains” and “contain”) areinclusive or open-ended and do not exclude additional, unrecitedelements or method steps.

The compositions and methods for their use can “comprise,” “consistessentially of,” or “consist of” any of the ingredients or stepsdisclosed throughout the specification. With respect to the transitionalphase “consisting essentially of,” in one non-limiting aspect, a basicand novel characteristic of the compositions and methods disclosed inthis specification includes the compositions' abilities to reduce orprevent symptoms associated with sensitive skin (e.g., erythema) fromappearing on a user's skin.

Other objects, features and advantages of the present invention willbecome apparent from the following detailed description. It should beunderstood, however, that the detailed description and the examples,while indicating specific embodiments of the invention, are given by wayof illustration only. Additionally, it is contemplated that changes andmodifications within the spirit and scope of the invention will becomeapparent to those skilled in the art from this detailed description.

DESCRIPTION OF ILLUSTRATIVE EMBODIMENTS

People afflicted with sensitive skin are susceptible to skin reactionswith current products on the market that include active ingredientstargeted towards a specific skin condition such as fine lines andwrinkles, loss of elasticity, hyperpigmentation, melasma, dry skin, oilyskin, acne, etc. While treatment of a particular skin condition can bebeneficial, it can also result in adverse effects such as producingreddened or inflamed skin in people that have sensitive skin. Thepresent invention offers a solution to this problem by providing acombination of ingredients that can be used on sensitive skin withoutproducing a skin-irritating reaction such as erythema/reddening of theskin.

These and other non-limiting aspects of the present invention areprovided in the following subsections.

A. Combination of Ingredients

The present invention is premised on a discovery of a combination ofingredients—hydrolyzed algin, escin, Ruscus aculeatus root extract,ammonium glycyrrhizate, Centella asiatica extract, hydrolyzed yeastprotein, and Calendula officinalis flower extract—that can be used toalleviate or even prevent symptoms associated with sensitive skin. Theseingredients are discussed in more detail below.

Hydrolyzed algin is a hydrolysate of algin. This ingredient iscommercially available from a variety of sources (see, e.g., CTFA,Volume 1, page 1211, which is incorporated by reference). An exemplarysource can be obtained from Barnet Products Corporation under the tradename Phyko-Al-PF. It has been discovered that this ingredient can beused to reduce the production of a variety of pro-inflammatory cytokinesand CGRP production (See Example 1).

Escin, also known as aescin, is a mixture of saponins found in the seedof Aesculus hippocastanum (the horse chestnut). This active ingredientis commercially available from a variety of sources (see, e.g.,International Cosmetic Ingredient Dictionary and Handbook, 12^(th)Edition, 2008 (“CTFA”), Volume 1, page 940, which is incorporated byreference).

Ruscus aculeatus root extract is an extract from the root of a lowevergreen Eurasian shrub in the Asparagaceae family. It is native tonorthern European and Eurasian countries. This extract is commerciallyavailable from a variety of sources (see, e.g., CTFA, Volume 2, page2405, which is incorporated by reference). In some embodiments, theextract can be an aqueous, alcoholic, or hydro-alcoholic extract.

Ammonium glycyrrhizate is an ammonium salt of glycyrrhizic acid, and iscommercially available from a variety of sources (see, e.g., CTFA,Volume 1, page 154, which is incorporated by reference).

The Centella asiatica plant is a small herbaceous plant that is nativeto countries such as India, Sri Lanka, Australia, Indonesia, Malaysia,Melanesia, Papua New Guinea, and other parts of Asia. Extracts from thisplant are commercially available from a wide range of sources (see,e.g., CTFA, Volume 1, pages 458-60, which is incorporated by reference).In particular embodiments, the whole plant extract can be used (seepages 458-59 of the CTFA). An exemplary source can be obtained fromBayer Sante Familiale SAS (France) under the trade name TECA (TitratedExtract of Centella Asiatica), which includes asiaticoside, madecassicacid, and asiatic acid. In some embodiments, the extract can be anaqueous, alcoholic, or hydro-alcoholic extract.

Hydrolyzed yeast protein is a hydrolysate of yeast proteins. This activeingredient is commercially available from a variety of sources (see,e.g., CTFA, Volume 1, page 1242, which is incorporated by reference).

Calendula officinalis flower extract is an extract of the Calendula(Calendula officinalis) flowers. The plant is native to central, easternand southern Europe. It is commercially available from a wide variety ofsources (see, e.g., CTFA, Volume 1, pages 388-390, which is incorporatedby reference). In some embodiments, the extract can be an aqueous,alcoholic, or hydro-alcoholic extract.

Additionally, a blend of escin, Ruscus aculeatus root extract, ammoniumglycyrrhizate, Centella asiatica extract, hydrolyzed yeast protein, andCalendula officinalis flower extract can be purchased under the tradename Biphytex™ LS 9832 from BASF Care Creations. It has been discoveredthat this blend can be used as an anti-oxidant (See Example 1). Theblend can be used in amounts ranging from 0.01 to 2% by weight.

B. Amounts of Ingredients

It is contemplated that the compositions of the present invention caninclude any amount of the ingredients discussed in this specification.The compositions can also include any number of combinations ofadditional ingredients described throughout this specification (e.g.,pigments, or additional cosmetic or pharmaceutical ingredients). Theconcentrations of the any ingredient within the compositions can vary.In non-limiting embodiments, for example, the compositions can comprise,consisting essentially of, or consist of, in their final form, forexample, at least about 0.0001%, 0.0002%, 0.0003%, 0.0004%, 0.0005%,0.0006%, 0.0007%, 0.0008%, 0.0009%, 0.0010%, 0.0011%, 0.0012%, 0.0013%,0.0014%, 0.0015%, 0.0016%, 0.0017%, 0.0018%, 0.0019%, 0.0020%, 0.0021%,0.0022%, 0.0023%, 0.0024%, 0.0025%, 0.0026%, 0.0027%, 0.0028%, 0.0029%,0.0030%, 0.0031%, 0.0032%, 0.0033%, 0.0034%, 0.0035%, 0.0036%, 0.0037%,0.0038%, 0.0039%, 0.0040%, 0.0041%, 0.0042%, 0.0043%, 0.0044%, 0.0045%,0.0046%, 0.0047%, 0.0048%, 0.0049%, 0.0050%, 0.0051%, 0.0052%, 0.0053%,0.0054%, 0.0055%, 0.0056%, 0.0057%, 0.0058%, 0.0059%, 0.0060%, 0.0061%,0.0062%, 0.0063%, 0.0064%, 0.0065%, 0.0066%, 0.0067%, 0.0068%, 0.0069%,0.0070%, 0.0071%, 0.0072%, 0.0073%, 0.0074%, 0.0075%, 0.0076%, 0.0077%,0.0078%, 0.0079%, 0.0080%, 0.0081%, 0.0082%, 0.0083%, 0.0084%, 0.0085%,0.0086%, 0.0087%, 0.0088%, 0.0089%, 0.0090%, 0.0091%, 0.0092%, 0.0093%,0.0094%, 0.0095%, 0.0096%, 0.0097%, 0.0098%, 0.0099%, 0.0100%, 0.0200%,0.0250%, 0.0275%, 0.0300%, 0.0325%, 0.0350%, 0.0375%, 0.0400%, 0.0425%,0.0450%, 0.0475%, 0.0500%, 0.0525%, 0.0550%, 0.0575%, 0.0600%, 0.0625%,0.0650%, 0.0675%, 0.0700%, 0.0725%, 0.0750%, 0.0775%, 0.0800%, 0.0825%,0.0850%, 0.0875%, 0.0900%, 0.0925%, 0.0950%, 0.0975%, 0.1000%, 0.1250%,0.1500%, 0.1750%, 0.2000%, 0.2250%, 0.2500%, 0.2750%, 0.3000%, 0.3250%,0.3500%, 0.3750%, 0.4000%, 0.4250%, 0.4500%, 0.4750%, 0.5000%, 0.5250%,0.0550%, 0.5750%, 0.6000%, 0.6250%, 0.6500%, 0.6750%, 0.7000%, 0.7250%,0.7500%, 0.7750%, 0.8000%, 0.8250%, 0.8500%, 0.8750%, 0.9000%, 0.9250%,0.9500%, 0.9750%, 1.0%, 1.1%, 1.2%, 1.3%, 1.4%, 1.5%, 1.6%, 1.7%, 1.8%,1.9%, 2.0%, 2.1%, 2.2%, 2.3%, 2.4%, 2.5%, 2.6%, 2.7%, 2.8%, 2.9%, 3.0%,3.1%, 3.2%, 3.3%, 3.4%, 3.5%, 3.6%, 3.7%, 3.8%, 3.9%, 4.0%, 4.1%, 4.2%,4.3%, 4.4%, 4.5%, 4.6%, 4.7%, 4.8%, 4.9%, 5.0%, 5.1%, 5.2%, 5.3%, 5.4%,5.5%, 5.6%, 5.7%, 5.8%, 5.9%, 6.0%, 6.1%, 6.2%, 6.3%, 6.4%, 6.5%, 6.6%,6.7%, 6.8%, 6.9%, 7.0%, 7.1%, 7.2%, 7.3%, 7.4%, 7.5%, 7.6%, 7.7%, 7.8%,7.9%, 8.0%, 8.1%, 8.2%, 8.3%, 8.4%, 8.5%, 8.6%, 8.7%, 8.8%, 8.9%, 9.0%,9.1%, 9.2%, 9.3%, 9.4%, 9.5%, 9.6%, 9.7%, 9.8%, 9.9%, 10%, 11%, 12%,13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24%, 25%, 26%,27%, 28%, 29%, 30%, 35%, 40%, 45%, 50%, 60%, 65%, 70%, 75%, 80%, 85%,90%, 95%, or 99% or any range derivable therein, of at least one of theingredients that are mentioned throughout the specification and claims.In non-limiting aspects, the percentage can be calculated by weight orvolume of the total composition. A person of ordinary skill in the artwould understand that the concentrations can vary depending on theaddition, substitution, and/or subtraction of ingredients in a givencomposition.

C. Vehicles

The compositions of the present invention can be incorporated into alltypes of vehicles. Non-limiting examples include emulsions (e.g.,water-in-oil, water-in-oil-in-water, oil-in-water, silicone-in-water,water-in-silicone, oil-in-water-in-oil, oil-in-water-in-siliconeemulsions), creams, lotions, solutions (both aqueous andhydro-alcoholic), anhydrous bases (such as lipsticks and powders), gels,and ointments. Variations and other appropriate vehicles will beapparent to the skilled artisan and are appropriate for use in thepresent invention. In certain aspects, it is important that theconcentrations and combinations of the compounds, ingredients, andagents be selected in such a way that the combinations are chemicallycompatible and do not form complexes which precipitate from the finishedproduct.

D. Additional Ingredients

In addition to the combination of ingredients disclosed by theinventors, the compositions can also include additional ingredients suchas cosmetic ingredients and pharmaceutical active ingredients.Non-limiting examples of these additional ingredients are described inthe following subsections.

1. Cosmetic Ingredients

The CTFA International Cosmetic Ingredient Dictionary and Handbook (2004and 2008) describes a wide variety of non-limiting cosmetic ingredientsthat can be used in the context of the present invention. Examples ofthese ingredient classes include: fragrances (artificial and natural),dyes and color ingredients (e.g., Blue 1, Blue 1 Lake, Red 40, titaniumdioxide, D&C blue no. 4, D&C green no. 5, D&C orange no. 4, D&C red no.17, D&C red no. 33, D&C violet no. 2, D&C yellow no. 10, and D&C yellowno. 11), adsorbents, lubricants, solvents, moisturizers (including,e.g., emollients, humectants, film formers, occlusive agents, and agentsthat affect the natural moisturization mechanisms of the skin),water-repellants, UV absorbers (physical and chemical absorbers such asparaaminobenzoic acid (“PABA”) and corresponding PABA derivatives,titanium dioxide, zinc oxide, etc.), essential oils, vitamins (e.g. A,B, C, D, E, and K), trace metals (e.g. zinc, calcium and selenium),anti-irritants (e.g. steroids and non-steroidal anti-inflammatories),botanical extracts (e.g. aloe vera, chamomile, cucumber extract, ginkgobiloba, ginseng, and rosemary), anti-microbial agents, antioxidants(e.g., BHT and tocopherol), chelating agents (e.g., disodium EDTA andtetrasodium EDTA), preservatives (e.g., methylparaben andpropylparaben), pH adjusters (e.g., sodium hydroxide and citric acid),absorbents (e.g., aluminum starch octenylsuccinate, kaolin, corn starch,oat starch, cyclodextrin, talc, and zeolite), skin bleaching andlightening agents (e.g., hydroquinone and niacinamide lactate),humectants (e.g., sorbitol, urea, and manitol), exfoliants,waterproofing agents (e.g., magnesium/aluminum hydroxide stearate), skinconditioning agents (e.g., aloe extracts, allantoin, bisabolol,ceramides, dimethicone, hyaluronic acid, and dipotassium glycyrrhizate).Non-limiting examples of some of these ingredients are provided in thefollowing subsections.

a. UV Absorption Agents

UV absorption agents that can be used in combination with thecompositions of the present invention include chemical and physicalsunblocks. Non-limiting examples of chemical sunblocks that can be usedinclude para-aminobenzoic acid (PABA), PABA esters (glyceryl PABA,amyldimethyl PABA and octyldimethyl PABA), butyl PABA, ethyl PABA, ethyldihydroxypropyl PABA, benzophenones (oxybenzone, sulisobenzone,benzophenone, and benzophenone-1 through 12), cinnamates (octylmethoxycinnamate, isoamyl p-methoxycinnamate, octylmethoxy cinnamate,cinoxate, diisopropyl methyl cinnamate, DEA-methoxycinnamate, ethyldiisopropylcinnamate, glyceryl octanoate dimethoxycinnamate and ethylmethoxycinnamate), cinnamate esters, salicylates (homomethyl salicylate,benzyl salicylate, glycol salicylate, isopropylbenzyl salicylate, etc.),anthranilates, ethyl urocanate, homosalate, octisalate, dibenzoylmethanederivatives (e.g., avobenzone), octocrylene, octyl triazone, digalloytrioleate, glyceryl aminobenzoate, lawsone with dihydroxyacetone,ethylhexyl triazone, dioctyl butamido triazone, benzylidene malonatepolysiloxane, terephthalylidene dicamphor sulfonic acid, disodium phenyldibenzimidazole tetrasulfonate, diethylamino hydroxybenzoyl hexylbenzoate, bis diethylamino hydroxybenzoyl benzoate, bisbenzoxazoylphenyl ethylhexylimino triazine, drometrizole trisiloxane,methylene bis-benzotriazolyl tetramethylbutyiphenol, andbis-ethylhexyloxyphenol methoxyphenyltriazine,4-methylbenzylidenecamphor, and isopentyl 4-methoxycinnamate.Non-limiting examples of physical sunblocks include, kaolin, talc,petrolatum and metal oxides (e.g., titanium dioxide and zinc oxide).

b. Moisturizing Agents

Non-limiting examples of moisturizing agents that can be used with thecompositions of the present invention include amino acids, chondroitinsulfate, diglycerin, erythritol, fructose, glucose, glycerin, glycerolpolymers, glycol, 1,2,6-hexanetriol, honey, hyaluronic acid,hydrogenated honey, hydrogenated starch hydrolysate, inositol, lactitol,maltitol, maltose, mannitol, natural moisturizing factor, PEG-15butanediol, polyglyceryl sorbitol, salts of pyrollidone carboxylic acid,potassium PCA, propylene glycol, sodium glucuronate, sodium PCA,sorbitol, sucrose, trehalose, urea, and xylitol.

Other examples include acetylated lanolin, acetylated lanolin alcohol,alanine, algae extract, aloe barbadensis, aloe-barbadensis extract, aloebarbadensis gel, althea officinalis extract, apricot (prunus armeniaca)kernel oil, arginine, arginine aspartate, arnica montana extract,aspartic acid, avocado (persea gratissima) oil, barrier sphingolipids,butyl alcohol, beeswax, behenyl alcohol, beta-sitosterol, birch (betulaalba) bark extract, borage (Borago officinalis) extract, butcherbroom(Ruscus aculeatus) extract, butylene glycol, Calendula officinalisextract, Calendula officinalis oil, candelilla (euphorbia cerifera) wax,canola oil, caprylic/capric triglyceride, cardamon (elettariacardamomum) oil, carnauba (copernicia cerifera) wax, carrot (Daucuscarota sativa) oil, castor (ricinus communis) oil, ceramides, ceresin,ceteareth-5, ceteareth-12, ceteareth-20, cetearyl octanoate, ceteth-20,ceteth-24, cetyl acetate, cetyl octanoate, cetyl palmitate, chamomile(anthemis nobilis) oil, cholesterol, cholesterol esters, cholesterylhydroxystearate, citric acid, clary (salvia sclarea) oil, cocoa(theobroma cacao) butter, coco-caprylate/caprate, coconut (cocosnucifera) oil, collagen, collagen amino acids, corn (zea mays) oil,fatty acids, decyl oleate, dimethicone copolyol, dimethiconol, dioctyladipate, dioctyl succinate, dipentaerythrityl hexacaprylate/hexacaprate,DNA, erythritol, ethoxydiglycol, ethyl linoleate, eucalyptus globulusoil, evening primrose (oenothera biennis) oil, fatty acids, geraniummaculatum oil, glucosamine, glucose glutamate, glutamic acid,glycereth-26, glycerin, glycerol, glyceryl distearate, glycerylhydroxystearate, glyceryl laurate, glyceryl linoleate, glycerylmyristate, glyceryl oleate, glyceryl stearate, glyceryl stearate SE,glycine, glycol stearate, glycol stearate SE, glycosaminoglycans, grape(vitis vinifera) seed oil, hazel (corylus americana) nut oil, hazel(corylus avellana) nut oil, hexylene glycol, hyaluronic acid, hybridsafflower (carthamus tinctorius) oil, hydrogenated castor oil,hydrogenated coco-glycerides, hydrogenated coconut oil, hydrogenatedlanolin, hydrogenated lecithin, hydrogenated palm glyceride,hydrogenated palm kernel oil, hydrogenated soybean oil, hydrogenatedtallow glyceride, hydrogenated vegetable oil, hydrolyzed collagen,hydrolyzed elastin, hydrolyzed glycosaminoglycans, hydrolyzed keratin,hydrolyzed soy protein, hydroxylated lanolin, hydroxyproline, isocetylstearate, isocetyl stearoyl stearate, isodecyl oleate, isopropylisostearate, isopropyl lanolate, isopropyl myristate, isopropylpalmitate, isopropyl stearate, isostearamide DEA, isostearic acid,isostearyl lactate, isostearyl neopentanoate, jasmine (jasminumofficinale) oil, jojoba (buxus chinensis) oil, kelp, kukui (aleuritesmoluccana) nut oil, lactamide MEA, laneth-16, laneth-10 acetate,lanolin, lanolin acid, lanolin alcohol, lanolin oil, lanolin wax,lavender (lavandula angustifolia) oil, lecithin, lemon (citrus medicalimonum) oil, linoleic acid, linolenic acid, macadamia ternifolia nutoil, maltitol, matricaria (chamomilla recutita) oil, methyl glucosesesquistearate, methylsilanol PCA, mineral oil, mink oil, mortierellaoil, myristyl lactate, myristyl myristate, myristyl propionate,neopentyl glycol dicaprylate/dicaprate, octyldodecanol, octyldodecylmyristate, octyldodecyl stearoyl stearate, octyl hydroxystearate, octylpalmitate, octyl salicylate, octyl stearate, oleic acid, olive (oleaeuropaea) oil, orange (citrus aurantium dulcis) oil, palm (elaeisguineensis) oil, palmitic acid, pantethine, panthenol, panthenyl ethylether, paraffin, PCA, peach (prunus persica) kernel oil, peanut (arachishypogaea) oil, PEG-8 C12-18 ester, PEG-15 cocamine, PEG-150 distearate,PEG-60 glyceryl isostearate, PEG-5 glyceryl stearate, PEG-30 glycerylstearate, PEG-7 hydrogenated castor oil, PEG-40 hydrogenated castor oil,PEG-60 hydrogenated castor oil, PEG-20 methyl glucose sesquistearate,PEG40 sorbitan peroleate, PEG-5 soy sterol, PEG-10 soy sterol, PEG-2stearate, PEG-8 stearate, PEG-20 stearate, PEG-32 stearate, PEG40stearate, PEG-50 stearate, PEG-100 stearate, PEG-150 stearate,pentadecalactone, peppermint (mentha piperita) oil, petrolatum,phospholipids, polyamino sugar condensate, polyglyceryl-3 diisostearate,polyquaternium-24, polysorbate 20, polysorbate 40, polysorbate 60,polysorbate 80, polysorbate 85, potassium myristate, potassiumpalmitate, propylene glycol, propylene glycol dicaprylate/dicaprate,propylene glycol dioctanoate, propylene glycol dipelargonate, propyleneglycol laurate, propylene glycol stearate, propylene glycol stearate SE,PVP, pyridoxine dipalmitate, retinol, retinyl palmitate, rice (oryzasativa) bran oil, RNA, rosemary (rosmarinus officinalis) oil, rose oil,safflower (carthamus tinctorius) oil, sage (salvia officinalis) oil,sandalwood (santalum album) oil, serine, serum protein, sesame (sesamumindicum) oil, shea butter (butyrospermum parkii), silk powder, sodiumchondroitin sulfate, sodium hyaluronate, sodium lactate, sodiumpalmitate, sodium PCA, sodium polyglutamate, soluble collagen, sorbitanlaurate, sorbitan oleate, sorbitan palmitate, sorbitan sesquioleate,sorbitan stearate, sorbitol, soybean (glycine soja) oil, sphingolipids,squalane, squalene, stearamide MEA-stearate, stearic acid, stearoxydimethicone, stearoxytrimethylsilane, stearyl alcohol, stearylglycyrrhetinate, stearyl heptanoate, stearyl stearate, sunflower(helianthus annuus) seed oil, sweet almond (prunus amygdalus dulcis)oil, synthetic beeswax, tocopherol, tocopheryl acetate, tocopheryllinoleate, tribehenin, tridecyl neopentanoate, tridecyl stearate,triethanolamine, tristearin, urea, vegetable oil, water, waxes, wheat(triticum vulgare) germ oil, and ylang ylang (cananga odorata) oil.

c. Antioxidants

Non-limiting examples of antioxidants that can be used with thecompositions of the present invention include acetyl cysteine, ascorbicacid polypeptide, ascorbyl dipalmitate, ascorbyl methylsilanolpectinate, ascorbyl palmitate, ascorbyl stearate, BHA, BHT, t-butylhydroquinone, cysteine, cysteine HCl, diamylhydroquinone,di-t-butylhydroquinone, dicetyl thiodipropionate, dioleyl tocopherylmethylsilanol, disodium ascorbyl sulfate, distearyl thiodipropionate,ditridecyl thiodipropionate, dodecyl gallate, erythorbic acid, esters ofascorbic acid, ethyl ferulate, ferulic acid, gallic acid esters,hydroquinone, isooctyl thioglycolate, kojic acid, magnesium ascorbate,magnesium ascorbyl phosphate, methylsilanol ascorbate, natural botanicalanti-oxidants such as green tea or grape seed extracts,nordihydroguaiaretic acid, octyl gallate, phenylthioglycolic acid,potassium ascorbyl tocopheryl phosphate, potassium sulfite, propylgallate, quinones, rosmarinic acid, sodium ascorbate, sodium bisulfite,sodium erythorbate, sodium metabisulfite, sodium sulfite, superoxidedismutase, sodium thioglycolate, sorbityl furfural, thiodiglycol,thiodiglycolamide, thiodiglycolic acid, thioglycolic acid, thiolacticacid, thiosalicylic acid, tocophereth-5, tocophereth-10, tocophereth-12,tocophereth-18, tocophereth-50, tocopherol, tocophersolan, tocopherylacetate, tocopheryl linoleate, tocopheryl nicotinate, tocopherylsuccinate, and tris(nonylphenyl)phosphite.

d. Structuring Agents

In other non-limiting aspects, the compositions of the present inventioncan include a structuring agent. Structuring agent, in certain aspects,assist in providing rheological characteristics to the composition tocontribute to the composition's stability. In other aspects, structuringagents can also function as an emulsifier or surfactant. Non-limitingexamples of structuring agents include stearic acid, palmitic acid,stearyl alcohol, cetyl alcohol, behenyl alcohol, stearic acid, palmiticacid, the polyethylene glycol ether of stearyl alcohol having an averageof about 1 to about 21 ethylene oxide units, the polyethylene glycolether of cetyl alcohol having an average of about 1 to about 5 ethyleneoxide units, and mixtures thereof.

e. Emulsifiers

In certain aspects of the present invention, the compositions do notinclude an emulsifier. In other aspects, however, the compositions caninclude one or more emulsifiers. Emulsifiers can reduce the interfacialtension between phases and improve the formulation and stability of anemulsion. The emulsifiers can be nonionic, cationic, anionic, andzwitterionic emulsifiers (See McCutcheon's (1986); U.S. Pat. Nos.5,011,681; 4,421,769; 3,755,560). Non-limiting examples include estersof glycerin, esters of propylene glycol, fatty acid esters ofpolyethylene glycol, fatty acid esters of polypropylene glycol, estersof sorbitol, esters of sorbitan anhydrides, carboxylic acid copolymers,esters and ethers of glucose, ethoxylated ethers, ethoxylated alcohols,alkyl phosphates, polyoxyethylene fatty ether phosphates, fatty acidamides, acyl lactylates, soaps, TEA stearate, DEA oleth-3 phosphate,polyethylene glycol 20 sorbitan monolaurate (polysorbate 20),polyethylene glycol 5 soya sterol, steareth-2, steareth-20, steareth-21,ceteareth-20, PPG-2 methyl glucose ether distearate, ceteth-10,polysorbate 80, cetyl phosphate, potassium cetyl phosphate,diethanolamine cetyl phosphate, polysorbate 60, glyceryl stearate,PEG-100 stearate, and mixtures thereof.

f. Silicone Containing Compounds

In non-limiting aspects, silicone containing compounds include anymember of a family of polymeric products whose molecular backbone ismade up of alternating silicon and oxygen atoms with side groupsattached to the silicon atoms. By varying the —Si—O— chain lengths, sidegroups, and crosslinking, silicones can be synthesized into a widevariety of materials. They can vary in consistency from liquid to gel tosolids.

The silicone containing compounds that can be used in the context of thepresent invention include those described in this specification or thoseknown to a person of ordinary skill in the art. Non-limiting examplesinclude silicone oils (e.g., volatile and non-volatile oils), gels, andsolids. In certain aspects, the silicon containing compounds includes asilicone oils such as a polyorganosiloxane. Non-limiting examples ofpolyorganosiloxanes include dimethicone, cyclomethicone,polysilicone-11, phenyl trimethicone, trimethylsilylamodimethicone,stearoxytrimethylsilane, or mixtures of these and other organosiloxanematerials in any given ratio in order to achieve the desired consistencyand application characteristics depending upon the intended application(e.g., to a particular area such as the skin, hair, or eyes). A“volatile silicone oil” includes a silicone oil have a low heat ofvaporization, i.e. normally less than about 50 cal per gram of siliconeoil. Non-limiting examples of volatile silicone oils include:cyclomethicones such as Dow Corning 344 Fluid, Dow Corning 345 Fluid,Dow Corning 244 Fluid, and Dow Corning 245 Fluid, Volatile Silicon 7207(Union Carbide Corp., Danbury, Conn.); low viscosity dimethicones, i.e.dimethicones having a viscosity of about 50 cst or less (e.g.,dimethicones such as Dow Corning 200-0.5 cst Fluid). The Dow CorningFluids are available from Dow Corning Corporation, Midland, Mich.Cyclomethicone and dimethicone are described in the Third Edition of theCTFA Cosmetic Ingredient Dictionary (incorporated by reference) ascyclic dimethyl polysiloxane compounds and a mixture of fully methylatedlinear siloxane polymers end-blocked with trimethylsiloxy units,respectively. Other non-limiting volatile silicone oils that can be usedin the context of the present invention include those available fromGeneral Electric Co., Silicone Products Div., Waterford, N.Y. and SWSSilicones Div. of Stauffer Chemical Co., Adrian, Mich.

g. Essential Oils

Essential oils include oils derived from herbs, flowers, trees, andother plants. Such oils are typically present as tiny droplets betweenthe plant's cells, and can be extracted by several method known to thoseof skill in the art (e.g., steam distilled, enfleurage (i.e., extractionby using fat), maceration, solvent extraction, or mechanical pressing).When these types of oils are exposed to air they tend to evaporate(i.e., a volatile oil). As a result, many essential oils are colorless,but with age they can oxidize and become darker. Essential oils areinsoluble in water and are soluble in alcohol, ether, fixed oils(vegetal), and other organic solvents. Typical physical characteristicsfound in essential oils include boiling points that vary from about 160°to 240° C. and densities ranging from about 0.759 to about 1.096.

Essential oils typically are named by the plant from which the oil isfound. For example, rose oil or peppermint oil are derived from rose orpeppermint plants, respectively. Non-limiting examples of essential oilsthat can be used in the context of the present invention include sesameoil, macadamia nut oil, tea tree oil, evening primrose oil, Spanish sageoil, Spanish rosemary oil, coriander oil, thyme oil, pimento berriesoil, rose oil, anise oil, balsam oil, bergamot oil, rosewood oil, cedaroil, chamomile oil, sage oil, clary sage oil, clove oil, cypress oil,eucalyptus oil, fennel oil, sea fennel oil, frankincense oil, geraniumoil, ginger oil, grapefruit oil, jasmine oil, juniper oil, lavender oil,lemon oil, lemongrass oil, lime oil, mandarin oil, marjoram oil, myrrhoil, neroli oil, orange oil, patchouli oil, pepper oil, black pepperoil, petitgrain oil, pine oil, rose otto oil, rosemary oil, sandalwoodoil, spearmint oil, spikenard oil, vetiver oil, wintergreen oil, orylang ylang. Other essential oils known to those of skill in the art arealso contemplated as being useful within the context of the presentinvention.

h. Thickening Agents

Thickening agents, including thickener or gelling agents, includesubstances which that can increase the viscosity of a composition.Thickeners includes those that can increase the viscosity of acomposition without substantially modifying the efficacy of the activeingredient within the composition. Thickeners can also increase thestability of the compositions of the present invention. In certainaspects of the present invention, thickeners include hydrogenatedpolyisobutene or trihydroxystearin, or a mixture of both.

Non-limiting examples of additional thickening agents that can be usedin the context of the present invention include carboxylic acidpolymers, crosslinked polyacrylate polymers, polyacrylamide polymers,polysaccharides, and gums. Examples of carboxylic acid polymers includecrosslinked compounds containing one or more monomers derived fromacrylic acid, substituted acrylic acids, and salts and esters of theseacrylic acids and the substituted acrylic acids, wherein thecrosslinking agent contains two or more carbon-carbon double bonds andis derived from a polyhydric alcohol (see U.S. Pat. Nos. 5,087,445;4,509,949; 2,798,053; CTFA International Cosmetic Ingredient Dictionary,Fourth edition, 1991, pp. 12 and 80). Examples of commercially availablecarboxylic acid polymers include carbomers, which are homopolymers ofacrylic acid crosslinked with allyl ethers of sucrose or pentaerytritol(e.g., Carbopol™ 900 series from B. F. Goodrich).

Non-limiting examples of crosslinked polyacrylate polymers includecationic and nonionic polymers. Examples are described in U.S. Pat. Nos.5,100,660; 4,849,484; 4,835,206; 4,628,078; 4,599,379).

Non-limiting examples of polyacrylamide polymers (including nonionicpolyacrylamide polymers including substituted branched or unbranchedpolymers) include polyacrylamide, isoparaffin and laureth-7, multi-blockcopolymers of acrylamides and substituted acrylamides with acrylic acidsand substituted acrylic acids.

Non-limiting examples of polysaccharides include cellulose,carboxymethyl hydroxyethylcellulose, cellulose acetate propionatecarboxylate, hydroxyethylcellulose, hydroxyethyl ethylcellulose,hydroxypropylcellulose, hydroxypropyl methylcellulose, methylhydroxyethylcellulose, microcrystalline cellulose, sodium cellulosesulfate, and mixtures thereof. Another example is an alkyl substitutedcellulose where the hydroxy groups of the cellulose polymer ishydroxyalkylated (preferably hydroxy ethylated or hydroxypropylated) toform a hydroxyalkylated cellulose which is then further modified with aC₁₀-C₃₀ straight chain or branched chain alkyl group through an etherlinkage. Typically these polymers are ethers of C₁₀-C₃₀ straight orbranched chain alcohols with hydroxyalkylcelluloses. Other usefulpolysaccharides include scleroglucans comprising a linear chain of (1-3)linked glucose units with a (1-6) linked glucose every three unit.

Non-limiting examples of gums that can be used with the presentinvention include acacia, agar, algin, alginic acid, ammonium alginate,amylopectin, calcium alginate, calcium carrageenan, carnitine,carrageenan, dextrin, gelatin, gellan gum, guar gum, guarhydroxypropyltrimonium chloride, hectorite, hyaluroinic acid, hydratedsilica, hydroxypropyl chitosan, hydroxypropyl guar, karaya gum, kelp,locust bean gum, natto gum, potassium alginate, potassium carrageenan,propylene glycol alginate, sclerotium gum, sodium carboyxmethyl dextran,sodium carrageenan, tragacanth gum, xanthan gum, and mixtures thereof.

i. Preservatives

Non-limiting examples of preservatives that can be used in the contextof the present invention include quaternary ammonium preservatives suchas polyquaternium-1 and benzalkonium halides (e.g., benzalkoniumchloride (“BAC”) and benzalkonium bromide), parabens (e.g.,methylparabens and propylparabens), phenoxyethanol, benzyl alcohol,chlorobutanol, phenol, sorbic acid, thimerosal or combinations thereof.

2. Pharmaceutical Ingredients

Pharmaceutical active agents are also contemplated as being useful withthe compositions of the present invention. Non-limiting examples ofpharmaceutical active agents include anti-acne agents, agents used totreat rosacea, analgesics, anesthetics, anorectals, antihistamines,anti-inflammatory agents including non-steroidal anti-inflammatorydrugs, antibiotics, antifungals, antivirals, antimicrobials, anti-canceractives, scabicides, pediculicides, antineoplastics, antiperspirants,antipruritics, antip soriatic agents, anti seborrheic agents,biologically active proteins and peptides, burn treatment agents,cauterizing agents, depigmenting agents, depilatories, diaper rashtreatment agents, enzymes, hair growth stimulants, hair growthretardants including DFMO and its salts and analogs, hemostatics,kerotolytics, canker sore treatment agents, cold sore treatment agents,dental and periodontal treatment agents, photosensitizing actives, skinprotectant/barrier agents, steroids including hormones andcorticosteroids, sunburn treatment agents, sunscreens, transdermalactives, nasal actives, vaginal actives, wart treatment agents, woundtreatment agents, wound healing agents, etc.

E. Kits

Kits are also contemplated as being used in certain aspects of thepresent invention. For instance, compositions of the present inventioncan be included in a kit. A kit can include a container. Containers caninclude a bottle, a metal tube, a laminate tube, a plastic tube, adispenser, a pressurized container, a barrier container, a package, acompartment, a lipstick container, a compact container, cosmetic pansthat can hold cosmetic compositions, or other types of containers suchas injection or blow-molded plastic containers into which thedispersions or compositions or desired bottles, dispensers, or packagesare retained. The kit and/or container can include indicia on itssurface. The indicia, for example, can be a word, a phrase, anabbreviation, a picture, or a symbol.

The containers can dispense a pre-determined amount of the composition.In other embodiments, the container can be squeezed (e.g., metal,laminate, or plastic tube) to dispense a desired amount of thecomposition. The composition can be dispensed as a spray, an aerosol, aliquid, a fluid, or a semi-solid. The containers can have spray, pump,or squeeze mechanisms. A kit can also include instructions for employingthe kit components as well the use of any other compositions included inthe container. Instructions can include an explanation of how to apply,use, and maintain the compositions.

EXAMPLES

The following examples are included to demonstrate certain non-limitingaspects of the invention. It should be appreciated by those of skill inthe art that the techniques disclosed in the examples which followrepresent techniques discovered by the inventor to function well in thepractice of the invention. However, those of skill in the art should, inlight of the present disclosure, appreciate that many changes can bemade in the specific embodiments which are disclosed and still obtain alike or similar result without departing from the spirit and scope ofthe invention.

Example 1 Efficacy of Ingredients Inhibition of Pro-InflammatoryCytokines

Hydrolyzed algin was found to inhibit production of a variety ofpro-inflammatory cytokines in primary adult human keratinocytes (Cascade#C-005-5C) using a MesoScale Discovery SECTOR Imager 2400. The Imager2400 was used to detect and calculate the amount of a selectedpro-inflammatory cytokine present in a sample. A summary of these dataare provided in Table 1.

TABLE 1* Pro-Inflammatory Cytokine % Change From Control** TNF-α −37IL-6 −70 IL-8 −33 IL-10 −40 IL-12 p40 −32 GM-CSF −28 *1% hydrolyzedalgin was used and was obtained from Barnet Products Corporation underthe trade name Phyko-AL-PF. **Control used was 0.5% DMSO. % Change FromControl = % Pro-inflammatory Cytokine - % Pro-Inflammatory Cytokine ofControl. Therefore, a negative (−) indicates inhibition of cytokineproduction.

The procedure used to obtain the data in Table 1 included the followingsteps:

-   -   Cell Culture—HEKa: HEKa cells were grown to subconfluence from a        frozen vial in 3×T75 tissue culture flasks (37° C., 5% CO2).        Confluent T75s (P1-P3) were washed with HBSS then trypsinized        with 1.5 ml trypsin for ˜4 min at 37° C. Cells were collected in        4 ml TNS, then spin in 15 ml conical tubes and resuspended in        Epilife media and plate in 6 well dishes. Test compounds were        diluted to 1% and 0.1% in media+1 Ong/ml PMA. Upon reaching 85%        confluence, the cells were washed and the media was replaced        with 2 ml diluted test compound for 4-6 hrs (37° C., 5% CO2). 2        ml media was collected from each well, aliquot, and freeze at        −80° C. until assayed with Procollagen peptide kit (PIP). All        media was removed from cells, and 1 mL diluted MTS reagent was        added to each well, incubated for 15-30 min (37° C., 5% CO2),        and the plate was read at 490 nm.    -   Step 1: Samples may not require dilution prior to use in the        assay. Bring appropriate diluents and plates to room temperature        and thaw cytokine calibrators on ice. Store detection antibody        mix at 4° C.; shield from light. Prepare calibrator solutions        and calibration curve. (If applicable). Use the 1 μg/mL        calibrator stock to prepare an 8-point calibration curve of        10,000, 2500, 625, 156, 39, 9.8, 2.4, and 0 pg/mL. The        calibration curve can be modified as necessary to meet specific        assay requirements. Prepare Detection Antibody Solution by        diluting the Detection Antibody to 1 μg/mL in 3.0 mL of HSC.        Antibody Diluent (per plate) (serum/plasma samples), or Antibody        Diluent (tissue culture samples). Keep this reagent in the dark.        Prepare 25 mL of 2× Read Buffer T by diluting 4× Read Buffer T        1:2 with deionized water. Continue with assay using appropriate        protocol below.    -   Step 2: For MULTI-SPOT Assays with IFN-γ, Dispense 150 μL/well        1% Blocker B Solution. For MULTI-SPOT Assays with IL-12p40,        dispense 150 μL/well 0.1% Blocker B Solution. Incubate at room        temperature with vigorous shaking (300-1000 rpm) for 1 hour.        Wash plate 3× with PBS or other standard buffer. Dispense 25        μL/well Calibrator or Sample. Incubate at room temperature with        vigorous shaking (300-1000 rpm) for 1-2 hours.    -   Step 3: Dispense 25 μL/well 1 μg/mL Detection Antibody Solution.        Incubate at room temperature with vigorous shaking (300-1000        rpm) for 1-2 hours.    -   Step 4: Wash plate 3× with PBS-0.05% Tween-20. Dispense 150        μL/well 2× Read Buffer T. Analyze plate on SECTOR Imager 2400        instrument.

Inhibition of CGRP Production

Hydrolyzed algin was found to inhibit production of CGRP by humanepidermal keratinocytes. The endpoint of this assay is direct detectionarray analyzed by the Meso Scale Discovery system SECTOR 2400 Imager.The Imager 2400 was used to detect and calculate the amount of a CGRPpresent in a sample. A similar procedure to that used in the Inhibitionof Pro-Inflammatory Cytokines assay above was used to find that a 1%hydrolyzed algin blend inhibits CGRP production in primary adult humankeratinocytes (Cascade #C-005-5C). An average inhibition of 65.70% overcontrol was seen.

Antioxidative Properties

A blend of Escin, Ruscus aculeatus root extract, Centella asiaticaextract, Hydrolyzed yeast protein, Calendula officinalis flower extract,and Ammonium glycyrrhizate was found to have antioxidative propertiesusing the Oxygen Radical Absorption Capacity (ORAC) assay (Zen-Bio ORACAnti-oxidant Assay kit (#AOX-2)). This assay measures the loss offluorescein fluorescence over time due to the peroxyl-radical formationby the breakdown of AAPH (2,2′-axobis-2-methyl propanimidamide,dihydrochloride). Trolox, a water soluble vitamin E analog, serves aspositive control inhibition fluorescein decay in a dose dependentmanner. A summary of these data are provided in Table 2.

TABLE 2* % Better than 100 μM Blend Amount Trolox % Better thanUntreated 0.1% 201.31 276.21 0.01% 48.69 136.31 0.001% −73.80 24.02*Blend of Escin, Ruscus aculeatus root extract, Centella asiaticaextract, Hydrolyzed yeast protein, Calendula officinalis flower extract,and Ammonium glycyrrhizate used was Biophytex ™ LS 9832 and can beobtained from BASF Care Creations.

The procedure used to obtain the data in Table 2 included the followingsteps:

-   -   Step 1: Warm the plate reader incubation chamber to 37° C.        Set-up plate reader to perform a kinetic read for 30 minutes        with 1 minute intervals. Excitation=480 nm; Emission=520 nm.    -   Step 2: Prepare fluorescein working solution from the stock        solution provided by transferring 16.8 ml of Assay Buffer to an        empty tube (not provided) and adding 1.2 ml stock fluorescein        solution. Mix and protect from light.    -   Step 3: Prepare Trolox standards as follows: Briefly spin down        the contents of the 1.5 mM Trolox standard tube after thawing.        Pipette 580 μl of Assay Buffer into the 1.5 mM Trolox standard        tube provided and mix well by vortexing. This produces a diluted        stock Trolox standard of 50 M. Pipette 50 μl of assay buffer        into 6 tubes. Using the newly diluted stock Trolox solution,        prepare a dilution series. Mix each new dilution thoroughly        before proceeding to the next. The 50 M stock dilution serves as        the highest standard, and the assay buffer serves as the zero        standard.    -   Step 4: Add 150 μl of the working fluorescein solution to each        well of the assay plate provided.    -   Step 5: Add 25 μl of samples or Trolox standards to individual        wells of the assay plate provided, add 25 μl of assay buffer to        individual wells as a negative control. Place plate at 37° C.        for at least 5 minutes.    -   Step 6: While the assay plate is equilibrating to 37° C.,        prepare the AAPH Working Solution by adding 2.7 ml Assay Buffer        to the tube provided and gently invert. Place the working        solution on ice until needed. AAPH solution is good for 8 hours        if kept on ice.    -   Step 7: To begin the assay, add 25 μl of the AAPH working        solution to each of the wells containing standards and samples        from step 5. Place the assay plate in the plate reader and begin        kinetic fluorescence reading.

Example 2 Formulations

Formulations having the ingredients from Example 1 were prepared as afreshener/toner (Table 3), mask (Table 4), and gel (Table 5 and Table6).

TABLE 3* % Concentration Ingredient (by weight) Water 88 Butylene glycol6 Glycerin 4.5 Propylene glycol 0.56 Diazolidinyl urea 0.3PPG-5-Ceteth-20 0.17 Methylparaben 0.11 Sodium citrate 0.07 DisodiumEDTA 0.05 Buteth-3 0.04 Propylparaben 0.03 Citric acid 0.02 Sodiumbenzotriazolyl butylphenol sulfonate 0.02 Panthenol 0.01 Hydrolyzedalgin 0.007 Escin 0.003 Ruscus aculeatus root extract 0.0015 Ammoniumglycyrrhizate 0.001 Centella asiatica extract 0.00065 Hydrolyzed yeastprotein 0.0004 Calendula officinalis flower extract 0.00035 Excipients**q.s. *Formulation can be prepared by mixing the ingredients in a beakerunder heat 70-75° C. until homogenous. Subsequently, the formulation canbe cooled to standing room temperature (20-25° C.). **Excipients wereadded to modify the rheological properties of the composition.Alternatively, the amount of water can be varied so long as the amountof water in the composition is at least 80% w/w, and preferably between80 to 90% w/w.

TABLE 4* % Concentration Ingredient (by weight) Water 84 Pentyleneglycol 5 Polysilicone-11 2.9 Hydroxyethyl acrylate/sodiumacryloyldimethyl 1.9 taurate copolymer Dimethicone 1.4 Squalane 1.3Glyceryl undecylenate 1 Silica 0.5 Acrylates/C10-30 alkyl acrylatecrosspolymer 0.45 Butylene glycol 0.35 Triethanolamine 0.35 Polysorbate60 0.28 Hydroxypropyl cyclodextrin 0.08 Sorbitan isostearate 0.08Panthenol 0.05 Hydrolyzed algin 0.035 Glycerin 0.03 Escin 0.015 Ruscusaculeatus root extract 0.0075 Ammonium glycyrrhizate 0.005 Centellaasiatica extract 0.00325 Hydrolyzed yeast protein 0.002 Calendulaofficinalis flower extract 0.00175 Excipients** q.s. *Formulation can beprepared by mixing the ingredients in a beaker under heat 70-75° C.until homogenous. Subsequently, the formulation can be cooled tostanding room temperature (20-25° C.). **Excipients were added to modifythe rheological properties of the composition. Alternatively, the amountof water can be varied so long as the amount of water in the compositionis at least 80% w/w, and preferably between 80 to 90% w/w.

TABLE 5* % Concentration Ingredient (by weight) Water 86 Glycerin 5.4Pentylene glycol 4 Glycereth-26 2 Propylene glycol 0.56 Triethanolamine0.55 Acrylates/C10-30 alkyl acrylate crosspolymer 0.3 Diazolidinyl urea0.3 Hydroxyethylcellulose 0.2 Sodium polyacrylate 0.15 Methylparaben0.11 Disodium EDTA 0.1 Butylene glycol 0.07 Phenoxyethanol 0.05 Caprylylglycol 0.05 Propylparaben 0.03 Panthenol 0.01 Hydrolyzed algin 0.007Escin 0.003 Ruscus aculeatus root extract 0.0015 Ammonium glycyrrhizate0.001 Centella asiatica extract 0.00065 Hydrolyzed yeast protein 0.0004Calendula officinalis flower extract 0.00035 Excipients** q.s.*Formulation can be prepared by mixing the ingredients in a beaker underheat 70-75° C. until homogenous. Subsequently, the formulation can becooled to standing room temperature (20-25° C.). **Excipients were addedto modify the rheological properties of the composition. Alternatively,the amount of water can be varied so long as the amount of water in thecomposition is at least 80% w/w, and preferably between 80 to 90% w/w.

TABLE 6* % Concentration Ingredient (by weight) Water 86 Glycerin 5.4Pentylene glycol 4 Glycereth-26 2 Benzyl Alcohol 0.9 Triethanolamine0.55 Acrylates/C10-30 alkyl acrylate crosspolymer 0.3Hydroxyethylcellulose 0.2 Sodium polyacrylate 0.15 Disodium EDTA 0.1Hydroxypropyl cyclodextrin 0.08 Butylene glycol 0.07 Phenoxyethanol 0.05Caprylyl glycol 0.05 Panthenol 0.01 Hydrolyzed algin 0.007 Escin 0.003Ruscus aculeatus root extract 0.0015 Ammonium glycyrrhizate 0.001Centella asiatica extract 0.00065 Hydrolyzed yeast protein 0.0004Calendula officinalis flower extract 0.00035 Excipients** q.s.*Formulation can be prepared by mixing the ingredients in a beaker underheat 70-75° C. until homogenous. Subsequently, the formulation can becooled to standing room temperature (20-25° C.). **Excipients were addedto modify the rheological properties of the composition. Alternatively,the amount of water can be varied so long as the amount of water in thecomposition is at least 80% w/w, and preferably between 80 to 90% w/w.

All of the skin-active ingredients, compositions, or methods disclosedand claimed in this specification can be made and executed without undueexperimentation in light of the present disclosure. While theskin-active ingredients, compositions, or methods of this invention havebeen described in terms of particular embodiments, it will be apparentto those of skill in the art that variations may be applied to theskin-active ingredients, compositions, or methods and in the steps or inthe sequence of steps of the method described herein without departingfrom the concept, spirit and scope of the invention.

1. A method of treating oxidative damage in skin, the method comprisingtopically applying to skin having oxidative damage a compositioncomprising a therapeutically effective amount of: escin; Ruscusaculeatus root extract; ammonium glycyrrhizate; Centella asiaticaextract; hydrolyzed yeast protein; and Calendula officinalis flowerextract, wherein topical application of the composition to the skinhaving oxidative damage treats the skin, and wherein the oxidativedamaged skin inclues a fine line, a wrinkle, erythemic skin, or inflamedskin.
 2. The method of claim 1, wherein the composition reduces theformation of reactive oxygen species (ROS) in the skin.
 3. The method ofclaim 2, wherein the formation of ROS is from ultra-violet radiationexposure to the skin.
 4. The method of claim 2, wherein formation of ROSis from a chemical exposure to the skin.
 5. The method of claim 1,wherein the oxidative damaged skin includes a fine line.
 6. The methodof claim 1, wherein the oxidative damaged skin includes a wrinkle. 7.The method of claim 1, wherein the oxidative damaged skin includeserythemic skin.
 8. The method of claim 1, wherein the oxidative damagedskin includes inflamed skin.
 9. The method of claim 1, wherein thecomposition prevents reactive oxygen species (ROS) in the skin frominteracting with cellular mechanisms within the skin.
 10. The method ofclaim 1, wherein the composition is an emulsion.
 11. The method of claim10, wherein the emulstion is an oil-in-water emulsion.
 12. The method ofclaim 1, wherein the composition is a lotion or a cream.
 13. The methodof claim 1, wherein the composition is a gel.
 14. The method of claim 1,wherein the composition further comprises 80 to 90% by weight of water.15. The method of claim 1, wherein the composition comprises: 0.0001% to1% by weight of escin; 0.0001% to 1% by weight of Ruscus aculeatus rootextract; 0.0001% to 1% by weight of ammonium glycyrrhizate; 0.0001% to1% by weight of Centella asiatica extract; 0.0001% to 1% by weight ofhydrolyzed yeast protein; and 0.0001% to 1% by weight of Calendulaofficinalis flower extract.
 16. The method of claim 1, wherein thecomposition further comprises butylene glycol; glycerin; propyleneglycol; diazolidinyl urea; PPG-5-ceteth-20; methylparaben; sodiumcitrate; disodium EDTA; buteth-3; propylparaben; citric acid; sodiumbenzotriazolyl butylphenol sulfonate; and panthenol.
 17. The method ofclaim 1, wherein the composition further comprises glycerin; pentyleneglycol; glycereth-26; propylene glycol; triethanolamine; acrylates/C10-30 alkyl acrylate crosspolymer; diazolidinyl urea; hydroxyethylcellulose; sodium polyacrylate; methylparaben; disodium EDTA;butylene glycol; phenoxy ethanol; caprylyl glycol; propylparaben; andpanthenol.
 18. The method of claim 1, wherein the composition furthercomprises pentylene glycol; polysilicone-11; hydroxyethylacrylate/sodium acryloyldimethyl taurate copolymer; dimethicone;squalane; glyceryl undecylenate; silica; butylene glycol;triethanolamine; polysorbate 60; acrylates/C 10-30 alkyl acrylatecrosspolymer; hydroxypropyl cyclodextrin; sorbitan isostearate;panthenol; and glycerin.
 19. The method of claim 1, wherein thecomposition further comprises glycerin; pentylene glycol; glycereth-26;benzyl alcohol; triethanolamine; aerylates/C 10-30 alkyl acrylatecrosspolymer; hydroxy ethylcellulose; sodium polyacrylate; di sodiumEDTA; hydroxypropyl cyclodextrin; butylene glycol; phenoxy ethanol;caprylyl glycol; and panthenol.